Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy

Similar documents
Case Presentations in ILD. Harold R. Collard, MD Department of Medicine University of California San Francisco

Update on Therapies for Idiopathic Pulmonary Fibrosis. Outline

Diagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines

A Review of Interstitial Lung Diseases. Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco

Outline Definition of Terms: Lexicon. Traction Bronchiectasis

A Review of Interstitial Lung Diseases

CTD-related Lung Disease

Lines and crackles. Making sense of ILD

Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates

INTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018

Multidisciplinary Diagnosis in Action: Challenging Case Presentations

Disclosures. Clinical Approach: Evaluating CTD-ILD for the pulmonologist. ILD in CTD. connective tissue disease or collagen vascular disease

Pathologic Assessment of Interstitial Lung Disease

INTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF)

Disclosures. Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting. Relevant financial relationships: None. Off-label usage: None

4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs

Financial disclosure COMMON DIAGNOSES IN HRCT. High Res Chest HRCT. HRCT Pre test. I have no financial relationships to disclose. Anatomy Nomenclature

DIAGNOSTIC NOTE TEMPLATE

Annual Rheumatology & Therapeutics Review for Organizations & Societies

IPF: Epidemiologia e stato dell arte

Diagnosing ILD. What is important in 2016? Chris Grainge

Progress in Idiopathic Pulmonary Fibrosis

Non-neoplastic Lung Disease II

Diagnostic challenges in IPF

Patient with FVC>90% predicted. Demosthenes Bouros, Vasilios Tzilas University of Athens

Liebow and Carrington's original classification of IIP

Manish Powari Regional Training Day 10/12/2014

5/9/2015. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. No, I am not a pulmonologist! Radiology

IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK?

IPF - Inquadramento clinico

Interstitial Lung Disease (ILD)

NONE OVERVIEW FINANCIAL DISCLOSURES UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF (UIP) FOR PATHOLOGISTS. IPF = Idiopathic UIP Radiologic UIP Path UIP

Diffuse Interstitial Lung Diseases: Is There Really Anything New?

Disclosures. Traditional Paradigm. Overview 4/17/2010. I have relationships with the following organizations and companies:

Unpaid scientific collaborator & advisor with Veracyte, Inc.

11/10/2014. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. Radiology

Challenges in the Diagnosis of Interstitial Lung Disease

Hypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas

Dr. Tracy Luckhardt Division of Pulmonary, Allergy and Critical Care Medicine University of Alabama at Birmingham

Case 4 History. 58 yo man presented with prox IP joint swelling 2 months later pain and swelling in multiple joints Chest radiograph: bi-basilar

Histopathologic Approach to Interstitial Lung Disease

Current diagnostic recommendations for ILD: The multidisciplinary meeting TSANZSRS ASM

RADIOLOGIC EVALUATION OF PULMONARY NTM INFECTION. Tilman Koelsch, MD National Jewish Health - Department of Radiology

DIFFERENCES IN FIBROPROLIFERATIVE HEALING IN EXOGENEOUS AND IDIOPATHIC ILDs. ARE THERE ANY?

Guidelines for Diagnosis and Treatment of IPF

Idiopathic Pulmonary Fibrosis Treatable and Not Idiopathic

Wim Wuyts. Treatment of idiopathic interstitial pneumonias. March 12 th Interstitial lung diseases state of the art.

A case of a patient with IPF treated with nintedanib. Prof. Kreuter and Prof. Heussel

Timely Topics in Pulmonary Medicine

Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment

The Egyptian Journal of Hospital Medicine (July 2017) Vol.68 (2), Page

Nintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis

Interstitial Lung Disease

New Therapies and Trials in IPF

CLEARING THE AIR ON DIFFUSE PARENCHYMAL (INTERSTITIAL) LUNG DISEASE (ILD)

National Jewish Health. Idiopathic Pulmonary Fibrosis: A Guide for Providers

ILD and systemic disease

Interstitial Lung Disease

RADIOLOGIC EVALUATION OF PULMONARY NTM INFECTION. Tilman Koelsch, MD National Jewish Health - Department of Radiology

Challenges in the Diagnosis of Interstitial Lung Disease

Definition, classification and epidemiology

International consensus statement on idiopathic pulmonary fibrosis

Disclosures. IPF Medications: Practical Experience. Prednisone, Azathioprine, N acyetylcysteine. Case 1. Brett Ley, MD, MAS Assistant Professor, UCSF

Usual Interstitial pneumonia and Nonspecific Interstitial Pneumonia. Nitra and the Gangs.

Case 1 : Question. 1.1 What is the intralobular distribution? 1. Centrilobular 2. Perilymphatic 3. Random

ESBRIET (pirfenidone) oral capsule and oral tablet OFEV (nintedanib) oral capsule

Challenges in Pulmonary and Critical Care: 2018

Strategies for Updated Treatment Options for IPF

Disclosures. Integrated Approach to Treating CTD-ILD. Limitations. Relevant items to consider. Other than for SSc-ILD, no controlled data

Patient with IPF and no honeycombing on HRCT. Case 1 Demosthenes Bouros, Vasilios Tzilas University of Athens

Epidemiology and classification of smoking related interstitial lung diseases

INHALED TREPROSTINIL IN PULMONARY HYPERTENSION DUE TO INTERSTITIAL LUNG DISEASE (PH-ILD)

Interstitial Lung Disease and the Immune System

I don t need you. Disclosure Statement. Pathology Approach to ILD 11/5/2016. Kirk D. Jones, MD UCSF Dept of Pathology

Diagnosis of Connective Tissue Disease Interstitial Lung Disease in 2016

The radiological differential diagnosis of the UIP pattern

INTERSTITIAL LUNG DISEASE Dr. Zulqarnain Ashraf

Differential diagnosis

Challenges in Pulmonary and Critical Care 2017

9/12/18. Emerging Challenges in Primary Care: Navigating the Maze of Interstitial Lung Disease: Improving Outcomes through Early Diagnosis

The ABC s of ILD LIP AIP NSIP

Combined Unclassifiable Interstitial Pneumonia and Emphysema: A Report of Two Cases

Summary: Key Learning Points, Clinical Strategies, and Future Directions

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Experience with the Compassionate Use Program of nintedanib for the treatment of Idiopathic Pulmonary Fibrosis in Argentina

Katerina M. Antoniou, MD, PhD As. Professor in Thoracic Medicine ERS ILD Group Secretary Medical School, University of Crete Prague, June 2014

COI: no conflicts of interest to declare

NAVIGATING the NEW ERA in IPF: Idiopathic Pulmonary Fibrosis

* * APPROACH TO NON- NEOPLASTIC LUNG DISEASE IN TRANSBRONCHIAL AND SURGICAL BIOPSIES. Financial Disclosures: NONE. BIOPSY TECHNIQUES Bronchoscopic

Idiopathic pulmonary fibrosis

Hypersensitivity Pneumonitis: Epidemiology and Classification

UIP Possibile e Probabile

Interstitial Lung Disease: Clinical Approach to Diagnosis

Therapies for Idiopathic Pulmonary Fibrosis Pharmacologic, Non-Pharmacologic

I have no relevant conflicts of interest to disclose

Radiologic Approach to Smoking Related Interstitial Lung Disease

Challenges in the classification of fibrotic ILD

9/15/11. Dr. Vivien Hsu Director, UMDNJ Scleroderma Program New Brunswick, NJ September Scleroderma. Hard skin

Transcription:

Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy Jeff Swigris, DO, MS Director, ILD Program National Jewish Health

Disclosures Speaker - Boehringer Ingelheim and Genentech

Objectives Describe how to diagnose IPF Develop strategy to distinguish IPF from other ILDs Comprehensive therapeutic approach to IPF Patient education and taking aim at improving QOL

ILD Inflammation and/or scar In the INTERSTITIUM

To an ILD doc, the interstitium is located Along BV bundles In interlobular septae In the subpleural region Within alveolar walls (largest area)

Secondary Pulmonary Lobule ~1.5cm

Etiology-based classification scheme Exposure-related mold, bacteria, birds medications XRT dusts cigarette smoke ILD Genetic FPF Autoimmune-related RA Systemic sclerosis PM/DM Sjögren s syndrome MCTD SLE IBD Idiopathic Sarcoidosis LAM IIP

Idiopathic interstitial pneumonias (IIP) Major IIP Idiopathic pulmonary fibrosis (IPF) Idiopathic nonspecific interstitial pneumonia (NSIP) Respiratory bronchiolitis-ild (RB-ILD) Desquamative interstitial pneumonia (DIP) Cryptogenic organizing pneumonia (COP) Acute interstitial pneumonia (AIP)

ILD IIP IPF IPF: specific type of ILD within the IIP IPF: specific type of pulmonary fibrosis UIP-pattern IPF: Diagnosis of exclusion Rule out Exposure (environment, Rx, occupational) Connective tissue disease

Histology-based classification scheme FLAMMAT I ON S C AR UIP pattern lives here

Etiology-based classification scheme Exposure-related mold, bacteria, birds medications XRT dusts cigarette smoke INFLAMMAT I S C AR O N ILD Genetic FPF S C AR INFLAMMAT I N Autoimmune-related RA Systemic sclerosis PM/DM Sjögren s syndrome MCTD INFLAMMAT I S C AR O N O Idiopathic Sarcoidosis LAM IIP INFLAMMAT I S C AR O N

Pr N op ot e fo rty rr o f ep Pr ro es du en ct te io r n

Pr N op ot e fo rty rr o f ep Pr ro es du en ct te io r n

Idiopathic disease + UIP-pattern IPF

What to do when you have a patient in front of you and you are considering the possibility of IPF as the clinical summary diagnosis

Making the diagnosis of IPF You have to be a detective History Exam Pulmonary physiology Radiography +/- surgical lung biopsy

History

History Typically IPF presents with: Dyspnea subacute, insidious onset I thought it was just that I was a year older, 5# heavier, and out of shape +/- dry cough Fatigue/low stamina Not pain, swollen joints, rash

Identify symptoms of rheumatologic illness Eyes/skin/joints/muscles Family history Pulmonary fibrosis Rheumatologic illness Exposures History Smoking, dusts, M/M/B/B

Physical Exam

Physical examination Hands Chest Crackles Joints Skin ANY VELCRO CRACKLE IS ABNORMAL MAKE SURE YOU LISTEN AT THE BASES

Laboratory

Laboratory assessment Serologies ANA RF/anti-CCP Scl-70 SSA/SSB Myositis panel What to do with positive????

Pulmonary Physiology and Gas Exchange

Pulmonary physiology Pulmonary function testing Measures of resting and exercise-related gas exchange

Radiology ILD protocol HRCT No IV contrast Supine and prone Inspiratory and expiratory images High-resolution reconstruction algorithm 1-1.5mm thick slices

Lung Biopsy

Lung biopsy Transbronchial biopsy Sarcoidosis Lymphangitic carcinomatosis Subacute HP Surgical Thorascopic, multiple lobes When classic HRCT pattern absent

History Exam Labs Putting it all Together ANA, RF, anti-ccp Physiology Full PFTs Gas exchange 6MWT Radiology HRCT Pathology Integrate to get summary diagnosis

Making the diagnosis of IPF UIP-pattern IPF Suspected IPF Identifiable causes for ILD? No HRCT Possible UIP Indeterminate UIP Consider VATSx Lung Biopsy Clin/Rad/Path IPF or not IPF UIP Probable/Possible UIP Non-classifiable fibrosis Yes Other Dx Not UIP Not IPF

IPF CTD Park et al. AJRCCM 2007

Ann Intern Med. 2012;156(10):684-691

Pr N op ot e fo rty rr o f ep Pr ro es du en ct te io r n IPF: Cause of Death Olson et al. Am J Respir Crit Care Med 2007

What s not IPF? 48 yo F with achey joints, cracked hands, Raynauds and anti-pl-7 antibodies

What s the Diagnosis? 69 yo M with anti-ccp positive RA, now with cough and exertional dyspnea

What s not IPF? 69 yo M with parrot, exertional dyspnea and cough, VATSx bx = UIP-pattern with poorly-formed granulomas

What s not IPF? 73 yo F never-smoker, retired teacher, with chronic UTI on nitrofurantoin for > 4 years

What s not IPF? 53 yo F, executive secretary, uses her indoor hot tub daily, now with 4 months increasing dyspnea

What s the Diagnosis? 62 yo M former smoker, retired Air Force fighter pilot, no CTD symptoms, no exposures, VATSx bx with UIP-pattern histology

Therapeutic Maneuvers O2 keep SpO2 > 89% regardless of activity level Improves fatigue, functioning, dyspnea Pulmonary rehabilitation Improves fatigue, functioning, QOL Vaccinations

Therapeutic Maneuvers Probably look for and treat GERD, OSA, PH Education knowledge is power

Therapeutic Maneuvers Anti-fibrotics

Pathogenesis of IPF

Anti-fibrotics work here

Nintedanib or Pirfenidone Placebo Placebo P o 0 100 200 Placebo

Pirfenidone: adverse events Adverse Event Pirfenidone (%) Placebo (%) (%) (N = 278) (N = 277) Nausea 36 13.4 22.6 Rash 28.1 8.7 19.4 Dyspepsia 17.6 6.1 11.5 Anorexia 15.8 6.5 9.3 GERD 11.9 6.5 5.4 Weight Loss 12.6 7.9 4.7 Insomnia 11.2 6.5 4.7 Dizziness 17.6 13 4.6 Vomiting 12.9 8.7 4.2 King TE, et al. N Engl J Med. 2014

Nintedanib: Adverse Events Event INPULSIS-1 Nintedanib (n = 309) Placebo (n = 204) INPULSIS-2 Nintedanib (n = 329) Placebo (n = 219) Any (%) 96 89 94 90 Diarrhea (%) 62 19 63 18 Nausea (%) 23 6 26 7 Richeldi L, et al. N Engl J Med. 2014;370(22):2071 2082.

Summary Main Points IPF = idiopathic + UIP Thorough history, exam and HRCT Therapeutic approach: anti-fibrotics Simple things most important: Disease education O2 Pulmonary rehab